Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Compatibility of Nivestim Under Cytotoxic Chemotherapy in the Treatment of Malignant Diseases

Trial Profile

The Compatibility of Nivestim Under Cytotoxic Chemotherapy in the Treatment of Malignant Diseases

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary) ; Filgrastim (Primary)
  • Indications Chemotherapy induced febrile neutropenia; Neutropenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VENICE
  • Sponsors Hospira

Most Recent Events

  • 14 Oct 2016 Results published in the Advances in Therapy
  • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
  • 14 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top